Syngene International Share Price Target 2026 to 2030
Syngene International Ltd is India’s first integrated contract research and manufacturing services (CRAMS) company, offering end-to-end drug discovery, development, and manufacturing solutions to global pharmaceutical and biotech firms. A subsidiary of Biocon, Syngene has built a strong reputation as a reliable R&D partner with over 400 active clients, including 13 of the top 15 global pharma companies. However, recent financial performance shows slowing growth and margin pressure, raising questions about its current valuation. This article provides a balanced, fact-based outlook and realistic share price targets for each year from 2026 to 2030.
Business: Provides integrated drug discovery, development, and manufacturing services (CRAMS) across small molecules, biologics, and cell & gene therapy
Clients: Global pharma majors, emerging biotechs, agrochemicals, and consumer health companies
Ownership: 52.68% held by Biocon Ltd – making it a Biocon group company
Listed: Yes – on BSE (539337) and NSE (SYNGENE) since 2015
Clarifications:
Is Syngene a Biocon company? Yes – Biocon holds 52.68% stake; it’s a consolidated subsidiary.
What was the IPO price? ₹47 per share (April 2015).
Why is the share falling? Due to slowing revenue growth (5.3%), flat profits (0.32% YoY), and rich valuation (P/E ~58x).
Is it a good buy? Only for long-term, high-conviction investors who believe in India’s life sciences outsourcing story. Not suitable for short-term traders.
Target price? Realistic 2026 range: ₹520–₹590 (see detailed breakdown below).
Syngene International: Key Financial Snapshot
Metric
Value
Market Capitalization
₹19,260.50 Cr
Current Share Price
₹478
52-Week High / Low
₹651 / ₹420
P/E (TTM)
58.17
P/B (TTM)
4.15
Book Value (TTM)
₹115.08
EPS (TTM)
₹8.22
ROE
10.65%
ROCE
14.39%
Dividend Yield
0.26%
Debt
₹102.50 Cr
Cash Reserves
₹652.50 Cr
Sales Growth (YoY)
5.31%
Profit Growth (YoY)
0.32%
Shareholding Pattern
Category
Holding (%)
Promoters (Biocon)
52.68%
Domestic Institutions (DII)
25.84%
Foreign Institutions (FII)
14.96%
Public (Retail)
6.51%
Others
0%
Note: Strong promoter control ensures strategic alignment with Biocon’s vision.
Syngene Share Price Target Forecast (2026–2030)
Given the high P/E, modest growth, and competitive CRO landscape, upside is limited unless execution improves. Targets assume:
EPS CAGR of 8–10% (supported by stable but slow growth)
P/E compression from 58x to 40–45x by 2030
Sustained R&D client retention and new wins
Year
Target Price Range (₹)
2026
₹520 – ₹590
2027
₹550 – ₹630
2028
₹580 – ₹680
2029
₹610 – ₹730
2030
₹640 – ₹780
⚠️ Important: Even at ₹780 in 2030, P/E would be ~45x—still premium for a business with single-digit profit growth.
Year-wise Breakdown
Syngene Share Price Target 2026
Year
Target 1
Target 2
2026
₹520
₹590
Rationale: Near-term pressure continues due to low sales momentum and client concentration risk. Upside depends on Q4 FY26 order inflows.
Syngene Share Price Target 2027
Year
Target 1
Target 2
2027
₹550
₹630
Rationale: Potential benefit from new facility ramp-up (1.9 Mn sq. ft. infrastructure) and biologics expansion. But competition from global CROs remains intense.
Syngene Share Price Target 2028
Year
Target 1
Target 2
2028
₹580
₹680
Rationale: By 2028, if cell & gene therapy services gain traction, margins could improve. ROCE sustainability (~14%) supports modest re-rating.
Syngene Share Price Target 2029
Year
Target 1
Target 2
2029
₹610
₹730
Rationale: Long-term play on global pharma R&D outsourcing to India. Success depends on differentiation in complex modalities.
Syngene Share Price Target 2030
Year
Target 1
Target 2
2030
₹640
₹780
Rationale: The upper end assumes consistent EPS growth of 10%+ and debt-free balance sheet utilization. Still, valuation will likely remain stretched vs peers like Jubilant or Piramal.
Strengths vs Risks
✅ Strengths
Integrated CRAMS platform – rare in India
Strong client base (13/15 top pharma companies)
Debt-light (₹102 Cr debt vs ₹652 Cr cash)
Backed by Biocon – strategic stability
⚠️ Risks
Very high P/E (58x) with near-zero profit growth
Low ROE (10.6%) and ROCE (14.4%) – capital efficiency lags
Intense global competition from Charles River, Lonza, etc.
Minimal dividends (0.26% yield)
Investment Suitability
Factor
Assessment
Risk Profile
Moderate-to-High (premium CRO)
Time Horizon
Long-term (5+ years)
Volatility
High
Dividend/Income
None (0.26% yield)
Ideal Investor
Growth-focused investor bullish on India’s life sciences ecosystem
FAQs
Only if you accept high valuation risk. Fundamentals do not justify current multiples without significant growth acceleration.
Yes – Biocon owns 52.68%; it’s a consolidated subsidiary.
For 2026, a realistic range is ₹520–₹590. By 2030, it could reach ₹640–₹780.
₹47 per share (listed in April 2015).
Due to slowing growth, flat profits, and rich valuation, not business deterioration.
Final Verdict
Syngene International is a high-quality CRO with strong global linkages, but its current valuation is stretched relative to growth. Our 2026–2030 price targets (₹520–₹780) reflect cautious optimism—assuming steady execution but no major re-rating. Investors should wait for a P/E below 45x or profit growth above 10% before building large positions.
📌 Disclaimer: Price targets are estimates based on current fundamentals and sector trends. They are not investment advice. Please consult a SEBI-registered advisor before investing.
Hi, I’m Raj Mittal, a stock market content writer focused on company analysis, share price trends, and fundamental research. I create simple, research-based insights to help investors make smarter market decisions.
